Writing a Contamination Control Policy for Sterile Manufacturing

Contamination control and aseptic processing are at the heart of producing safe, effective, and sterile pharmaceutical products—especially in sterile manufacturing. With the latest updates to EU Annex 1 and guidance like PDA Technical Report 90, there’s a clear shift toward a more holistic, science- and risk-based approach. Rather than relying on isolated controls, the expectation now is to build an integrated Contamination Control Strategy (CCS) that connects facility design, operations, personnel practices, and lifecycle management into one cohesive system.

So, where do you begin when it comes to writing a policy?        

The first option is to align it directly with the Annex 1 framework—Scope, Purpose, Quality Management System (QMS), Facility, Equipment, Critical Utilities, Aseptic Technique, Production and Specific Technologies, Aseptic Process Simulation (APS), Environmental Monitoring (EM), Process Monitoring, and Quality Control (QC).

The second option is to organize it around your manufacturing process flow, tailoring the structure of your document to how operations are performed on the floor.

Both approaches are effective, but each comes with its own advantages and trade-offs depending on how you intend to use the document.

Approach Comparison: Annex 1 Structure vs. Manufacturing Process Flow                 

At the core of EU Annex 1 is the expectation that manufacturers establish, document, and continuously maintain a CCS. This strategy should not be a static document, but a living system that integrates quality risk management principles (e.g., ICH Q9) across all aspects of sterile manufacturing. PDA Technical Report 90 reinforces this by framing contamination control as a proactive and data-driven discipline, leveraging process understanding, trending, and continuous improvement. Together, these frameworks shift the industry from reactive deviation management to predictive contamination prevention.

So, what is harrisbpa approach?

If a formal CCS has not yet been established, alignment with the framework outlined in EU GMP Annex 1 provides a structured and regulatorily accepted starting point. This approach compels a comprehensive evaluation of all elements influencing contamination risk. The outcome is a holistic view of how contamination is prevented, detected, and controlled across the lifecycle of sterile manufacturing.

For organizations with an existing policy seeking to evolve toward a more process-specific risk-based CCS, the logical entry point is a formal risk assessment to identify and justify critical controls. This ensures the strategy is science- and risk-based, rather than purely prescriptive.

A robust risk assessment begins with detailed process mapping. This should encompass the full manufacturing workflow, including raw materials and excipients, product-contact equipment and single-use systems, container-closure systems, critical utilities, facility and engineering controls, and defined critical quality attributes (CQAs) at each stage. The resulting process flow diagram serves as the foundation for systematic risk evaluation.

The preferred methodology for this assessment is Hazard Analysis and Critical Control Points (HACCP). HACCP provides a structured approach to identifying potential hazards, evaluating their impact, and determining where controls are necessary. Through cross-functional engagement, each step in the process is assessed to classify it as either a control point or a critical control point. This distinction is driven by the level of risk and the rigor of the associated monitoring and control strategy.

Upon completion of the HACCP, the CCS policy should consolidate and clearly articulate both critical control points and supporting control measures. While maintaining alignment with the intent of Annex 1, the document should reflect a risk-based, process-specific narrative. Rather than broadly stating that operations occur within classified environments, the CCS should describe how controls are implemented and verified—for example, detailing the use of Grade A environments in conjunction with sterile single-use systems, continuous environmental monitoring, and defined in-process controls. In this form, the CCS evolves from a static policy into a transparent, integrated strategy that is both operationally meaningful and readily interpretable by regulatory authorities.

What should your company report, and should I establish recurring meetings? If so, what should those meetings look like?

Your company should report metrics aligned with defined control points. This approach provides clear visibility into whether operations remain in a steady state of control and helps trigger timely corrective or preventive actions before deviations occur.

Regular, recurring meetings should be an established expectation to assess facility performance and drive continuous improvement. Depending on production schedules and operational demands, these reviews may occur monthly or quarterly. Facilities running continuous manufacturing should adopt monthly meetings to ensure processes remain consistently controlled.

Meeting formats may vary. Some sessions may take a comprehensive view of all elements outlined in the contamination control policy, while others may focus on key indicators and performance trends.

So, what is harrisbpa approach?

From a Harrisbpa perspective, these meetings should be anchored to the Critical Control Points (CCPs) identified through the CCS risk assessment. Reporting should emphasize adverse trends and any results that fall outside established baselines, as these signal potential or emerging contamination risks. From a Quality Management System (QMS) standpoint, the review should also cover critical deviations, change controls, and CAPAs that may influence the CCS risk profile. Each session should include dedicated time for continuous improvement discussion. This may involve breakout discussions or focused reviews driven by the data presented. The goal is to ensure the CCS remains a dynamic, actively managed system rather than a static framework.

In summary, contamination control and aseptic processing are no longer viewed as discrete compliance activities but as interconnected systems requiring scientific rigor, operational discipline, and continuous oversight. Alignment with EU Annex 1 and PDA Technical Report 90 demands a comprehensive, risk-based CCS that is actively maintained and continuously improved—ensuring that sterile products meet the highest standards of quality and patient safety.